Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2018

View Archived Issues

FDA grants QIDP designation to ACX-362E to treat C. difficile infection

Metastatic breast cancer regression by immunotherapy with TILs enriched for neoantigen reactivity

PTC Therapeutics presents updated preliminary data from FIREFISH

Reata initiates first-in-human study with allosteric RORgammat inhibitor RTA-1701

Preliminary data presented from first-in-human phase I trial on MTL-CEBPA

First-in-human data presented for novel monoclonal anti-IL-6R-alpha antibody BCD-089

HTX-011 receives breakthrough therapy designation and reaches primary endpoint in phase IIb studies

Researchers present primary efficacy data on PRO-140 from CD02 study

MaaT Pharma enters agreement for GvHD microbiome therapy

New dUTPase inhibitors synthesized at CV6 Therapeutics

Bristol-Myers Squibb describes glycogen synthase kinase 3 inhibitors

Dual MetAP 2/DPP-IV inhibitors identified at Lilly

Statins improve venetoclax anticancer activity in hematologic malignancies

FDA grants regenerative medicine advanced therapy designation for VY-AADC

Alpha Biopharma closes series A financing for phase II study of AZD-3759

ACKR3 gene copy number variations linked to pregnancy loss

Ironwood initiates phase III trials of IW-3718 in persistent GERD

Attenuated vaccine candidate shows rapid probiotic-like protection from cholera in animal models

Revance initiates phase III program with RT-002 injectable for cervical dystonia

FDA accepts sBLA for Opdivo plus low-dose Yervoy for first-line NSCLC

Phase II/III trial of NBTXR-3 in soft tissue sarcoma meets primary endpoint

Synairgen reports interim data from phase II trial of SNG-001 in COPD

Takeda acquires control of TiGenix

REACH1 study of ruxolitinib in steroid-refractory acute GvHD meets primary endpoint

FDA accepts IND for lanifibranor in patients with type 2 diabetes and NAFLD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...